The new platform will support research programs spanning oncology, hematology, cardiovascular disease, immunology and neuroscience. Bristol Myers Squibb plans to use the system to train foundation models with its proprietary scientific data while enabling agentic AI workflows for target identification, target validation and its "Predict First" approach, which uses AI-generated insights to guide experimental design before laboratory testing.
"BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations," said Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. "Expanding our compute capabilities with Nvidia gives our researchers and teams across the business the scale they need to keep BMS at the leading edge of what AI can do for drug discovery and development."
Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb, said the company's focus is on improving research quality rather than simply increasing development speed. "The goal isn't speed for its own sake; it's raising the probability that each program we advance is the right one," Plenge said.
As part of the expanded agreement, Bristol Myers Squibb will also gain access to Nvidia's BioNeMo platform for biological AI and the BioNeMo Agent Toolkit. The technologies are intended to help researchers apply AI to biological data and support molecule design and hypothesis generation.
Rory Kelleher, Senior Director of Business Development, Healthcare and Life Sciences at Nvidia, said the platform will help Bristol Myers Squibb turn its scientific datasets into proprietary intelligence for drug discovery research.
The companies did not disclose the financial terms of the agreement.
The deployment also reflects Bristol Myers Squibb's continued investment in on-premises AI infrastructure for research workloads. The system will support computational tasks across the company's drug discovery pipeline while allowing it to use its proprietary scientific data to train and run AI models internally.
The agreement further expands Nvidia's presence in the pharmaceutical industry, where the company has been supplying AI computing platforms for research-focused organizations. With the addition of the DGX SuperPOD and BioNeMo technologies, Bristol Myers Squibb is increasing the computing resources available for AI-assisted research across multiple therapeutic areas.
This analysis is based on reporting from Yahoo Finance.
Image courtesy of NVIDIA.
This article was generated with AI assistance and reviewed for accuracy and quality.
